Advertisement

Hepatocellular Carcinoma Arising in the Non-viral, Non-alcoholic Liver

  • Charles E. WoodallIII
  • Robert C. G. MartinII
  • Kelly M. McMasters
  • Charles R. Scoggins
Chapter

Abstract

Hepatocellular carcinoma is one of the five most common cancers worldwide and is one of the top three in regard to annual mortality. Greater than 80% occur in either sub-Saharan Africa or East Asia, and most of these cases are attributed to viral hepatitis. Increased public awareness and educational campaigns have led to decreasing incidences in these endemic areas. However, the rate of HCC in a number of areas with traditionally low rates of viral hepatitis, including Australia, the United States, Canada, and the United Kingdom, has increased significantly. This rising incidence cannot be easily explained by changes in immigration, hepatitis C virus, or ethanol.

Keywords

HCC risk factors HCC in the non-fibrotic liver Non-cirrhotic hepatoma Fibrolamellar carcinoma (FLC) Hereditary hemochromatosis (HH) Non-alcoholic fatty liver disease (NAFLD) 

References

  1. 1.
    Botha JF, Langnas AN (2006) Liver transplantation for hepatocellular carcinoma: an update. J Natl Compr Canc Netw 4:762–767.PubMedGoogle Scholar
  2. 2.
    El Serag HB, Davila JA, Petersen NJ et al (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823PubMedGoogle Scholar
  3. 3.
    Davila JA, Morgan RO, Shaib Y et al (2004) Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127:1372–1380CrossRefPubMedGoogle Scholar
  4. 4.
    Martin RC, Loehle J, Scoggins CR et al (2007) Kentucky hepatoma: epidemiologic variant or same problem in a different region? Arch Surg 142:431–436.CrossRefPubMedGoogle Scholar
  5. 5.
    Yancik R, Ries LA (2000) Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14:17–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Muss HB (2001) Older age–not a barrier to cancer treatment. N Engl J Med 345:1127–1128CrossRefGoogle Scholar
  7. 7.
    Reichman TW, Bahramipour P, Barone A et al (2005) Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. J Gastrointest Surg 9 ;638–645CrossRefPubMedGoogle Scholar
  8. 8.
    Fong Y, Sun RL, Jarnagin W et al (1999) An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229 :790–799CrossRefPubMedGoogle Scholar
  9. 9.
    Figueras J, Ramos E, Ibanez L et al (1999) Surgical treatment of hepatocellular carcinoma in cirrhotic and noncirrhotic patients. Transplant Proc 31:2455–2456CrossRefPubMedGoogle Scholar
  10. 10.
    Torzilli G, Makuuchi M, Inoue K et al (1999) No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 134:984–992CrossRefPubMedGoogle Scholar
  11. 11.
    Tsukioka G, Kakizaki S, Sohara N et al (2006) Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival. World J Gastroenterol 12:48–53Google Scholar
  12. 12.
    Edmonson H (1956) Differential diagnosis of tumors and tumor-like lesion of liver in infancy and childhood. AMA J Dis Child 91:168–186Google Scholar
  13. 13.
    El-Serag HB, Davila JA (2004) Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 39:798–803CrossRefPubMedGoogle Scholar
  14. 14.
    Craig JR, Peters RL, Edmondson HA et al (1980) Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 46:372–379CrossRefPubMedGoogle Scholar
  15. 15.
    Ichikawa T, Federle MP, Grazioli L et al (1999) Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology 213:352–361PubMedGoogle Scholar
  16. 16.
    Pinna AD, Iwatsuki S, Lee RG et al (1997) Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 26:877–883CrossRefPubMedGoogle Scholar
  17. 17.
    Stipa F, Yoon SS, Liau KH et al (2006) Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 106:1331–1338CrossRefPubMedGoogle Scholar
  18. 18.
    Moreno-Luna LE, Arrieta O, Garcia-Leiva J et al (2005) Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer 5:142.CrossRefPubMedGoogle Scholar
  19. 19.
    Okuda K (2002) Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 17:401–405.CrossRefPubMedGoogle Scholar
  20. 20.
    Hemming AW, Langer B, Sheiner P et al (1997) Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg 1:342–346CrossRefPubMedGoogle Scholar
  21. 21.
    Patt YZ, Hassan MM, Lozano RD et al (2003) Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21:421–427CrossRefPubMedGoogle Scholar
  22. 22.
    Vauthey JN, Klimstra D, Franceschi D et al (1995) Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 169:28–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Nagorney DM, Adson MA, Weiland LH et al (1985) Fibrolamellar hepatoma. Am J Surg 149:113–119CrossRefPubMedGoogle Scholar
  24. 24.
    Soreide O, Czerniak A, Bradpiece H et al (1986) Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature. Am J Surg 151:518–523CrossRefPubMedGoogle Scholar
  25. 25.
    Schlitt HJ, Ringe B, Rodeck B et al (1992) Bone marrow dysfunction after liver transplantation for fulminant non-A, non-B hepatitis. High risk for young patients. Transplantation 54:936–937CrossRefPubMedGoogle Scholar
  26. 26.
    Busuttil RW, Farmer DG (1996) The surgical treatment of primary hepatobiliary malignancy. Liver Transpl Surg 2:114–130PubMedGoogle Scholar
  27. 27.
    Ichikawa T, Federle MP, Grazioli L et al (2000) Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology 214:861–868PubMedGoogle Scholar
  28. 28.
    El-Gazzaz G, Wong W, El-Hadary MK et al (2000) Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int 13(Suppl 1):S406–S409CrossRefPubMedGoogle Scholar
  29. 29.
    Kohler HH, Hohler T, Kusel U et al (1999) Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report. Pathol Res Pract 195:509–513PubMedGoogle Scholar
  30. 30.
    Merryweather-Clarke AT, Pointon JJ, Shearman JD et al. (1997) Global prevalence of putative haemochromatosis mutations. J Med Genet 34:275–278CrossRefPubMedGoogle Scholar
  31. 31.
    Pietrangelo A (2004) Hereditary hemochromatosis–a new look at an old disease. N Engl J Med 350:2383–2397CrossRefPubMedGoogle Scholar
  32. 32.
    Niederau C, Fischer R, Purschel A et al (1996) Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110:1107–1119CrossRefPubMedGoogle Scholar
  33. 33.
    Niederau C, Fischer R, Sonnenberg A et al (1985) Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313:1256–1262CrossRefPubMedGoogle Scholar
  34. 34.
    Elmberg M, Hultcrantz R, Ekbom A et al (2003) Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125:1733–1741.CrossRefPubMedGoogle Scholar
  35. 35.
    Hsing AW, McLaughlin JK, Olsen JH et al (1995) Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 60:160–162CrossRefPubMedGoogle Scholar
  36. 36.
    Fargion S, Mandelli C, Piperno A et al (1992) Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 15:655–659CrossRefPubMedGoogle Scholar
  37. 37.
    Fracanzani AL, Conte D, Fraquelli M et al (2001) Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 33:647–651CrossRefPubMedGoogle Scholar
  38. 38.
    von DS, Lersch C, Schulte-Frohlinde E et al (2006) Hepatocellular carcinoma associated with hereditary hemochromatosis occurring in non-cirrhotic liver. Z Gastroenterol 44:39–42CrossRefGoogle Scholar
  39. 39.
    Sato K, Ueda Y, Ueno K et al (2005) Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch 447:996–999CrossRefPubMedGoogle Scholar
  40. 40.
    Britto MR, Thomas LA, Balaratnam N et al (2000) Hepatocellular carcinoma arising in non-cirrhotic liver in genetic haemochromatosis. Scand J Gastroenterol 35:889–893Google Scholar
  41. 41.
    Gomaa AI, Khan SA, Toledano MB et al (2008) Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14:4300–4308Google Scholar
  42. 42.
    Ludwig J, Viggiano TR, McGill DB et al (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434–438PubMedGoogle Scholar
  43. 43.
    Bacon BR, Farahvash MJ, Janney CG et al (1994) Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103–1109PubMedGoogle Scholar
  44. 44.
    Yoshioka Y, Hashimoto E, Yatsuji S et al (2004) Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol 39:1215–1218CrossRefPubMedGoogle Scholar
  45. 45.
    Mori S, Yamasaki T, Sakaida I et al (2004) Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 39:391–396CrossRefPubMedGoogle Scholar
  46. 46.
    Cuadrado A, Orive A, Garcia-Suarez C et al (2005) Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 15:442–446CrossRefPubMedGoogle Scholar
  47. 47.
    Bugianesi E (2007) Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 11, 191–198Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Charles E. WoodallIII
    • 1
  • Robert C. G. MartinII
    • 2
  • Kelly M. McMasters
    • 3
  • Charles R. Scoggins
    • 2
  1. 1.Surgical Oncology/Surgical EndoscopyFerrell Duncan Clinic General Surgery, CoxHealthSpringfieldUSA
  2. 2.Division of Surgical Oncology, Department of SurgeryUniversity of Louisville School of MedicineLouisvilleUSA
  3. 3.Department of SurgeryUniversity of LouisvilleLouisvilleUSA

Personalised recommendations